Cookson Peirce & Co. Inc. Buys New Shares in Lineage Cell Therapeutics, Inc. $LCTX

Key Points

• Cookson Peirce & Co. Inc. purchased a new position in Lineage Cell Therapeutics, acquiring 250,000 shares valued at approximately $113,000.
• Several other institutional investors, including JPMorgan Chase & Co. and Renaissance Technologies LLC, significantly increased their stakes in Lineage Cell Therapeutics during the fourth quarter.
• Analysts maintain a predominantly positive outlook on the stock, with five analysts rating it as a buy and a current average price target of $4.20.

Cookson Peirce & Co. Inc. purchased a new stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 250,000 shares of the company's stock, valued at approximately $113,000. Cookson Peirce & Co. Inc. owned about 0.11% of Lineage Cell Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Two Sigma Advisers LP increased its position in shares of Lineage Cell Therapeutics by 312.2% during the 4th quarter. Two Sigma Advisers LP now owns 86,964 shares of the company's stock valued at $44,000 after purchasing an additional 65,864 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in Lineage Cell Therapeutics in the 4th quarter worth approximately $46,000. ORG Partners LLC purchased a new stake in Lineage Cell Therapeutics in the 1st quarter worth approximately $47,000. Wells Fargo & Company MN increased its holdings in Lineage Cell Therapeutics by 33.0% in the 4th quarter. Wells Fargo & Company MN now owns 94,894 shares of the company's stock worth $48,000 after acquiring an additional 23,527 shares in the last quarter. Finally, Deutsche Bank AG increased its holdings in Lineage Cell Therapeutics by 196.0% in the 4th quarter. Deutsche Bank AG now owns 174,702 shares of the company's stock worth $87,000 after acquiring an additional 115,672 shares in the last quarter. Hedge funds and other institutional investors own 62.47% of the company's stock.

Lineage Cell Therapeutics Price Performance

Shares of NYSEAMERICAN LCTX traded down $0.0250 during midday trading on Thursday, hitting $1.1650. 326,355 shares of the company's stock were exchanged, compared to its average volume of 1,914,165. Lineage Cell Therapeutics, Inc. has a twelve month low of $0.3651 and a twelve month high of $1.31. The company has a market cap of $266.04 million, a PE ratio of -6.47 and a beta of 1.66. The firm's fifty day simple moving average is $1.01 and its 200-day simple moving average is $0.70.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. D. Boral Capital reissued a "buy" rating and issued a $2.00 target price on shares of Lineage Cell Therapeutics in a report on Thursday, August 14th. HC Wainwright reissued a "buy" rating and issued a $9.00 target price on shares of Lineage Cell Therapeutics in a report on Monday, June 23rd. Four equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Lineage Cell Therapeutics has a consensus rating of "Buy" and an average price target of $4.25.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.